Treatment compositions with modified amino acid multimers

A treatment composition comprising:

• a treatment adjunct, and
• 0.001% to 30% by weight of the treatment composition of a modified amino acid multimer compound,
• wherein the multimer compound comprises a central linking group and from two to six amino acid portions each covalently linked to the central linking group,
• wherein the central linking group comprises from 3 to 18 carbon atoms,
• wherein the central linking group does not comprise a peptide bond,
• wherein each amino acid portion comprises a carbonyl group at a C terminus, wherein the carbonyl group comprises a carbon atom,
• wherein the carbon atom of the carbonyl is bonded to a heteroatom of the central linking group,
• wherein the heteroatom is selected from the group consisting of O, S, and N,
• wherein each amino acid portion further comprises a nitrogen atom at an N terminus,
• wherein at least one amino acid portion comprises a benefit agent residue that is bonded to the nitrogen atom at the N terminus of the at least one amino acid portion,
• wherein a benefit agent is released when one or more bonds that connect the benefit agent residue to the amino acid portion are cleaved,
• wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof.

A treatment composition comprising:

• a treatment adjunct, and
• 0.001% to 30% by weight of the treatment composition of a modified amino acid multimer compound, wherein the modified amino acid multimer compound is characterized by a structure according to Formula I:
• L[E]t Formula I,
• wherein t is independently an integer from 2 to 6;
• wherein L is a central linking group that is multivalent and that comprises 3 to 18 carbon atoms;
• wherein the central linking group does not comprise a peptide bond;
• wherein each E group is independently selected from -GH, -GX, or a moiety according to Formula II:
• with the proviso that the multimer compound comprises at least two E groups that are moieties according to Formula II,
• wherein * indicates the point of attachment of the E group with L,
• wherein the value of x is from 1 to 9,
• wherein each G is independently selected from the group consisting of —O—, —N(R3)—, and —S—,
• wherein each R3, if present, is independently selected from H or a monovalent moiety with a molecular weight between 14 and 881 Da,
• wherein X, if present, is a suitable charge-balancing counterion,
• wherein each R1 is independently selected from H or a monovalent moiety with a molecular weight between 15 and 507 Da,
• wherein each R2 is independently selected from H and a monovalent moiety with a molecular weight of between 15 and 1000 Da,
• wherein each A group is a monovalent nitrogen-comprising moiety,
• wherein at least one A group comprises an independently selected benefit agent residue that is linked to the rest of the A group by one or more bonds,
• wherein a benefit agent is released when the one or more bonds are cleaved,
• wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof.